Program
selnoflast
Also written as “Selnoflast” and “RO7486967”.
Its studies are mostly in Atherosclerosis · Parkinson Disease, led by Hoffmann-La Roche.
Furthest: phase 2, since Feb 25, 20262 company-led studies, 1 open or runningNext primary completion: Jan 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 21 open or running | phase 2since Feb 25, 2026 | Jun 21, 2023 | Jan 31, 2028phase 2 · NCT07448038 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6418 selnoflast
, phase 2, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 21, 2023First study: phase 1 study in Parkinson DiseaseFirst studyNCT05924243 · 60 enrolled · United States, Netherlands, United Kingdom
- Feb 25, 2026Phase 2 study in AtherosclerosisPhase 2 reachedNCT07448038 · 162 planned · United States, Canada
Ahead
- Jan 31, 2028Primary completion: phase 2 study in AtherosclerosisNCT07448038
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07448038Atherosclerosis · United States, Canada | 2 | Recruiting | Jan 31, 2028 | 162 |
| NCT05924243Parkinson Disease · United States, Netherlands, United Kingdom | 1 | Completed | Jul 18, 2024 | 60 |
How it is read
Names in the registry
- “Selnoflast”, 1 entry
- “RO7486967”, 1 entry
Conditions, from the studies’ own filings
- Atherosclerosis, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.